Skip to main content

BIO-TECHNE Corp

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

TECH$72.82-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(in thousands)

​​​​​​​
​ · ​ ​ ​ · Quarter Ended
​ · ​ · September 30,
​ · ​ · 2026 · ​ · 2025
CASH FLOWS FROM OPERATING ACTIVITIES: · ​ · ​ · ​ · ​
Net earnings​$28,293​$38,185
Adjustments to reconcile net earnings to net cash provided by operating activities:​​​​
Depreciation and amortization​23,726​24,340
Deferred income taxes​2,444​5,275
Stock-based compensation expense​13,407​11,682
(Gain) Loss on equity method investment​​(1,776)​​(294)
(Gain) Loss on investments​​(325)​​(2,054)
Leases, net​(710)​(912)
Recovery of assets held-for-sale​​—​​(6,789)
Other operating activity​1,153​1,001
Change in operating assets and operating liabilities:​​​​
Trade accounts and other receivables, net​13,329​22,392
Inventories​(2,508)​(14,002)
Prepaid expenses​(1,489)​380
Trade accounts payable, accrued expenses, contract liabilities, and other​14,315​(2,115)
Salaries, wages and related accruals​(13,545)​(22,101)
Income taxes payable​(3,201)​(27,403)
Net cash provided by operating activities​73,113​27,585
​​​​​​​
CASH FLOWS FROM INVESTING ACTIVITIES:​​​​
Additions to property and equipment​(5,917)​(5,363)
Distributions from Wilson Wolf​​1,990​​1,351
Proceeds from sale of assets held-for-sale​​—​​4,617
Net cash used in investing activities​(3,927)​605
​​​​​​​
CASH FLOWS FROM FINANCING ACTIVITIES:​​​​
Cash dividends​(12,559)​(12,444)
Proceeds from stock option exercises​36,180​23,495
Repurchases of common stock​—​(24)
Repayments of long-term debt​—​(46,000)
Taxes paid on RSUs and net share settlements​​(7,236)​​(9,231)
Net cash used in financing activities​16,385​(44,204)
​​​​​​​
Effect of exchange rate changes on cash and cash equivalents​(247)​(1,210)
Net change in cash and cash equivalents​85,324​(17,224)
Cash and cash equivalents at beginning of period​264,712​162,186
Cash and cash equivalents at end of period​$350,036​$144,962
​​​​​​​
Supplemental disclosure of cash flow information:​​​​​​
Cash paid for income taxes​$6,822​$30,812
Cash paid for interest​$2,651​$4,822
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.